A patient population is a defined group of people who share specific health-related characteristics, such as a diagnosis, age range, risk level, or treatment setting. The term is used across healthcare delivery, clinical research, and public health to describe exactly which group of patients is being treated, studied, or managed. How that group gets defined depends entirely on the context.
How Patient Populations Are Defined
At its simplest, a population is people living in a particular place and time. A patient population narrows that down to people who share medical or demographic traits relevant to a specific purpose. A hospital might define its patient population as everyone enrolled in its chronic disease management program. A research team might define theirs as adults over 40 with a COPD diagnosis who are current or former smokers. A health insurer might define a patient population as members with two or more chronic conditions who visited the emergency department three or more times in the past year.
The defining characteristics typically fall into a few categories: demographics (age, sex, geographic location), clinical features (specific diagnoses, disease severity, medication use), and behavioral factors (smoking status, physical activity levels). These variables act as boundaries that determine who falls inside the population and who doesn’t.
Patient Populations in Clinical Research
In clinical trials, defining the patient population is one of the earliest and most consequential decisions researchers make. They do this through inclusion and exclusion criteria, which are formally required in any well-designed study protocol.
Inclusion criteria describe the key features someone must have to participate. These are the traits that make the group relevant to the research question. For example, a study on a new blood pressure medication might require participants to be at least 18, have a confirmed diagnosis of high blood pressure, and be currently taking no other blood pressure drugs.
Exclusion criteria filter out people who technically qualify but whose participation could skew results or put them at risk. Common exclusion factors include other medical conditions that could interfere with the data, a high likelihood of missing follow-up appointments, or an inability to provide accurate self-reported information. In a lung disease study, for instance, researchers might exclude patients with sleep apnea or other chronic respiratory conditions that would make it impossible to isolate the effect of the treatment being tested.
These choices have real consequences beyond the study itself. The tighter the criteria, the cleaner the data, but the harder it becomes to apply the results to the broader world. If a trial only enrolls men between 50 and 65 with no other health conditions, the findings may not hold true for women, younger adults, or people managing multiple diseases. Researchers are expected to evaluate how their inclusion and exclusion decisions will affect whether results can be generalized to a wider patient population.
The Gap Between Study Samples and Real Patients
Clinical research articles often blur the lines between three distinct groups: the target population (the broad group the researchers want their findings to apply to), the accessible population (the patients available at participating hospitals or clinics), and the achieved sample (the people who actually enrolled). Many studies struggle to clearly articulate these distinctions, which can make it difficult for readers to judge how broadly the results apply. A researcher working at a large urban academic medical center, for instance, may have an accessible population that looks very different from rural patients with the same condition.
Why the FDA Now Requires Diversity Plans
Historically, many clinical trials enrolled patient populations that were overwhelmingly white, male, and younger than the people who would eventually use the treatments being studied. This created a significant evidence gap. The FDA now requires sponsors of certain clinical studies to submit diversity action plans describing how they will improve enrollment of underrepresented populations. This requirement, mandated under the FDA Omnibus Reform Act, applies to the demographic makeup of trial participants by race, ethnicity, sex, and age. The goal is to ensure that the patient populations studied in trials more closely reflect the people who will actually receive the treatments.
Patient Populations in Healthcare Delivery
Outside of research, hospitals and health systems use patient population definitions to design care programs and allocate resources. A health system might identify five distinct patient populations within its network: high-cost patients, people with multiple chronic conditions, frail elderly patients, frequent emergency department visitors, and patients with repeated hospital admissions. Each group needs different services, staffing, and outreach strategies. Choosing which patient population to focus on shapes every downstream decision about how a program operates.
Electronic health records have made this kind of segmentation far more precise. Rather than relying on a single diagnosis code, health systems can now model patients using dozens of variables pulled from years of records, including demographics, vital signs, medication history, and the presence of related conditions. Machine learning tools can then group patients into clusters that share similar risk profiles. One study using six years of electronic health record data identified four clinically meaningful subgroups within a chronic disease management program: two with more severe disease profiles and two with milder ones. This kind of stratification helps care teams tailor their approach rather than offering the same intervention to everyone.
Patient Population vs. Population Health
These two terms overlap but point in different directions. A patient population is a specific group defined for a specific purpose: the 3,000 people with diabetes enrolled at a particular clinic, or the 200 participants in a drug trial. Population health is a broader concept that looks at the health outcomes of entire groups and, critically, the distribution of those outcomes within the group. It asks not just “how healthy is this population on average?” but “why are some subgroups doing worse than others?”
Population health also looks upstream at the forces that shape health before someone becomes a patient: income, education, housing, environmental exposures. The field traces back to an idea articulated by epidemiologist Geoffrey Rose, who argued that the most effective health strategy is shifting the entire distribution of risk in a favorable direction rather than treating individuals one at a time after they get sick. In practice, a hospital manages its patient population; a public health department pursues population health.
How Real-World Data Expands the Picture
Clinical trials are tightly controlled environments. Real-world evidence studies fill in the gaps by examining how diseases progress and how treatments perform in everyday clinical practice, using data from electronic medical records, insurance claims, and patient registries. These studies characterize patient populations as they actually exist: people with multiple conditions, inconsistent medication adherence, and varying access to care.
A retrospective study in Sweden, for example, pulled records from nearly 6,000 patients across 10 outpatient diabetes clinics to evaluate whether guidelines recommending quarterly blood sugar monitoring were actually being followed in practice. A multicenter study in India tracked a large group of people with type 2 diabetes over three years to identify real-world patterns in complications and treatment choices. These studies describe patient populations in their natural state, not filtered through trial criteria, and often reveal gaps between what guidelines recommend and what patients actually experience.
For healthcare systems, this kind of data makes it possible to characterize a patient population with far more nuance than a simple diagnosis label allows. Two people with the same condition can have vastly different risk levels, and identifying where each person falls within the broader patient population is what allows care to be matched to actual need.